WO2005039559A1 - 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 - Google Patents
血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 Download PDFInfo
- Publication number
- WO2005039559A1 WO2005039559A1 PCT/JP2004/016351 JP2004016351W WO2005039559A1 WO 2005039559 A1 WO2005039559 A1 WO 2005039559A1 JP 2004016351 W JP2004016351 W JP 2004016351W WO 2005039559 A1 WO2005039559 A1 WO 2005039559A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- arachidonic acid
- food
- genus
- fatty acid
- Prior art date
Links
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 201000010099 disease Diseases 0.000 title claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 32
- 230000032683 aging Effects 0.000 title claims abstract description 31
- 208000024891 symptom Diseases 0.000 title claims abstract description 28
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 311
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 155
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 155
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 70
- 229930195729 fatty acid Natural products 0.000 claims abstract description 70
- 239000000194 fatty acid Substances 0.000 claims abstract description 70
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 69
- 235000013305 food Nutrition 0.000 claims abstract description 62
- 239000000470 constituent Substances 0.000 claims abstract description 44
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 52
- 150000003626 triacylglycerols Chemical class 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 36
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 22
- 150000004667 medium chain fatty acids Chemical group 0.000 claims description 18
- 230000003449 preventive effect Effects 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 12
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 12
- 206010008118 cerebral infarction Diseases 0.000 claims description 11
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 11
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 244000005700 microbiome Species 0.000 claims description 11
- 241000235575 Mortierella Species 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 10
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 10
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 10
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 10
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- -1 alcohol ester Chemical class 0.000 claims description 9
- 208000031225 myocardial ischemia Diseases 0.000 claims description 9
- 208000006011 Stroke Diseases 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 241000228212 Aspergillus Species 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims description 3
- 241001480517 Conidiobolus Species 0.000 claims description 3
- 241001480508 Entomophthora Species 0.000 claims description 3
- 241000223218 Fusarium Species 0.000 claims description 3
- 241000233614 Phytophthora Species 0.000 claims description 3
- 241000233639 Pythium Species 0.000 claims description 3
- 241000233667 Saprolegnia Species 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 241001219832 Lobosporangium Species 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 241000228143 Penicillium Species 0.000 claims 2
- 235000013361 beverage Nutrition 0.000 abstract description 5
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 61
- 235000019198 oils Nutrition 0.000 description 61
- 239000003925 fat Substances 0.000 description 53
- 235000019197 fats Nutrition 0.000 description 53
- 241000700159 Rattus Species 0.000 description 37
- 108090001060 Lipase Proteins 0.000 description 24
- 102000004882 Lipase Human genes 0.000 description 24
- 239000004367 Lipase Substances 0.000 description 24
- 235000019421 lipase Nutrition 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 201000001320 Atherosclerosis Diseases 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 229930003427 Vitamin E Natural products 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 8
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 8
- 235000019165 vitamin E Nutrition 0.000 description 8
- 239000011709 vitamin E Substances 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 210000002376 aorta thoracic Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 6
- 108010093096 Immobilized Enzymes Proteins 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001196 vasorelaxation Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000020940 control diet Nutrition 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 229960004488 linolenic acid Drugs 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229960002446 octanoic acid Drugs 0.000 description 4
- 238000005809 transesterification reaction Methods 0.000 description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 235000021313 oleic acid Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- PWWHPNUWGBQCGO-WDEREUQCSA-N (2s)-n-[2-[[(2r)-4-methyl-2-(methylamino)pentanoyl]amino]acetyl]pyrrolidine-2-carboxamide Chemical compound CC(C)C[C@@H](NC)C(=O)NCC(=O)NC(=O)[C@@H]1CCCN1 PWWHPNUWGBQCGO-WDEREUQCSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000907999 Mortierella alpina Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 241000287463 Phalacrocorax Species 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 241000303962 Rhizopus delemar Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- SNXPWYFWAZVIAU-UHFFFAOYSA-N arachidonic acid ethyl ester Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)OCC SNXPWYFWAZVIAU-UHFFFAOYSA-N 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 230000002883 vasorelaxation effect Effects 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- WJQOZHYUIDYNHM-UHFFFAOYSA-N 2-tert-Butylphenol Chemical compound CC(C)(C)C1=CC=CC=C1O WJQOZHYUIDYNHM-UHFFFAOYSA-N 0.000 description 1
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 206010007687 Carotid artery stenosis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101710098556 Lipase A Proteins 0.000 description 1
- 101710099648 Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000048020 Mortierella exigua Species 0.000 description 1
- 241000133355 Mortierella hygrophila Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000235402 Rhizomucor Species 0.000 description 1
- 241000235403 Rhizomucor miehei Species 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000179532 [Candida] cylindracea Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 208000006170 carotid stenosis Diseases 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001966 cerebroprotective effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 230000000364 effect on atherosclerosis Effects 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000011251 protective drug Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention provides arachidonic acid or arachidonic acid as a constituent fatty acid.
- a composition comprising a compound as an active ingredient, which has a preventive or ameliorating effect on symptoms or diseases caused by aging of blood vessels, and a food or beverage having a statement on the action of preventing or ameliorating symptoms or diseases caused by aging of blood vessels, and a method for producing the same It is about.
- a composition having a preventive or ameliorating effect on atherosclerosis for example, ischemic heart disease (myocardial infarction, angina pectoris) or stroke (cerebral hemorrhage, cerebral infarction)
- atherosclerosis for example, ischemic heart disease (myocardial infarction, angina pectoris) or stroke (cerebral hemorrhage, cerebral infarction)
- the present invention also relates to a food and drink having an improving effect and a method for producing the same.
- Atherosclerosis is largely divided into three types: atherosclerosis, calcification of the media, and atherosclerosis.
- Atherosclerosis is clinically important, and the most common site is from the aorta to the limbs Arteries, coronary arteries, basilar arteries, etc. As atherosclerosis progresses, symptoms of ischemic heart disease, cerebral infarction including carotid artery stenosis, and obstructive atherosclerosis are observed, which impairs daily life and social life. Atherosclerosis risk factors include age as well as hypercholesterolemia
- Atherosclerotic diseases involve blood vessels.
- Polyunsaturated fatty acids mainly arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid, are bound to the phospholipids constituting the cell membrane of the blood vessels as constituent fatty acids.
- these polyunsaturated fatty acids cannot be synthesized de novo in animals, and are directly or indirectly (in the case of arachidonic acid, the precursor linoleic acid is replaced with eicosapentaenoic acid and docosahexaenoic acid). In this case, the precursor ⁇ -linolenic acid must be taken from the diet.
- polyunsaturated fatty acids including linoleic acid and poly-linolenic acid, have a blood cholesterol-lowering effect, and are associated with atherosclerosis. (Food and nutrition)
- Non-Patent Document 1 2000 Welfare White Paper
- Non-patent document 2 Pharmacy 54, 2245-2249, 2003
- Non-patent document 3 Pharmacy 54, 2287-2303, 2003
- Non-Patent Document 4 Food ⁇ Nutrition ⁇ Health, 72-78, 1991
- Non-patent document 5 Clinical nutrition 87, 254-259, 1995 Disclosure of the invention
- the present invention provides a composition having an effect of preventing or ameliorating symptoms or diseases caused by aging of blood vessels, comprising arachidonic acid or a compound having arachidonic acid as a constituent fatty acid as an active ingredient.
- An object of the present invention is to provide a food or drink having a preventive or ameliorating effect on symptoms or diseases caused by aging and a method for producing the same. More specifically, at least one selected from the group consisting of arachidonic acid, alcohol esters of arachidonic acid, triglycerides containing arachidonic acid as a constituent fatty acid, and phospholipids.
- a composition having a preventive or ameliorating effect on blood vessel elasticity as an active ingredient arteriosclerosis (for example, ischemic heart disease (myocardial infarction, angina pectoris) or stroke (cerebral hemorrhage, cerebral infarction)). It is intended to provide a food or drink having a preventive or ameliorating effect and a method for producing the same.
- arteriosclerosis for example, ischemic heart disease (myocardial infarction, angina pectoris) or stroke (cerebral hemorrhage, cerebral infarction)
- the present inventors have conducted intensive studies on arachidonic acid or a compound having arachidonic acid as a constituent fatty acid as an active ingredient for the purpose of clarifying the effect of preventing or ameliorating symptoms or diseases caused by aging of blood vessels. Surprisingly, old rats over 20 months of age were subjected to a vasorelaxation confirmation test to clarify the effect of the active ingredient of the present invention.
- the present invention succeeded in producing an oil or fat containing a triglyceride having a medium-chain fatty acid at the 1,3-position and arachidonic acid at the 2-position by an enzymatic method.
- the present invention can be used for an effect test, and the effect is clearly demonstrated. Therefore, according to the present invention, aging of blood vessels containing arachidonic acid or a compound having arachidonic acid as a constituent fatty acid is effective.
- a composition having a preventive or ameliorating effect on symptoms or diseases caused by the disease a food or drink having a preventive or ameliorating effect on symptoms or diseases caused by vascular aging, and a method for producing the same.
- At least one selected from the group consisting of arachidonic acid, alcohol esters of arachidonic acid, triglycerides containing arachidonic acid as a constituent fatty acid, and phospholipids is effective.
- arteriosclerosis for example, ischemia
- a composition having a preventive or ameliorating effect on sexual heart disease (myocardial infarction) or stroke (cerebral hemorrhage, cerebral infarction) a food or drink having a preventive or ameliorating effect, and a method for producing the same. It is especially useful for humans in modern society. Brief Description of Drawings
- FIG. 1 is a graph showing the relationship between acetylcholine concentration and the rate of vascular relaxation in an in vitro experiment using blood vessels of old rats.
- FIG. 2 is a graph showing the effect of a feed containing arachidonic acid on arachidonic acid content in the thoracic aorta of old rats.
- FIG. 3 is a graph showing the relationship between the arachidonic acid content in blood vessels and the vascular relaxation rate in old rats.
- the present invention relates to a composition having a preventive or ameliorating effect on aging of a blood vessel or a disease, comprising arachidonic acid or a compound containing arachidonic acid as a constituent fatty acid, and a symptom resulting from aging of a blood vessel.
- the present invention relates to a food or drink having a preventive or ameliorating effect on disease and a method for producing the same.
- Symptoms or diseases caused by aging of blood vessels include decreased elasticity of blood vessels and arteriosclerosis (eg, ischemic heart disease (myocardial infarction, angina pectoris) ⁇ stroke (cerebral hemorrhage, cerebral infarction)) Although it can be, these symptoms or diseases are not limited to, but include all symptoms or diseases caused by aging of blood vessels.
- arteriosclerosis eg, ischemic heart disease (myocardial infarction, angina pectoris)
- stroke Cerebral hemorrhage, cerebral infarction
- the fatty acid composition of the phospholipids in rat blood vessels produced by the parents of the high-fat diet group was compared with that of rats produced by the parent of the normal diet group, even if they were reared on a normal diet after weaning.
- the amount of arachidonic acid decreased.
- conventional foods contain 0.13% of arachidonic acid, the effects of arachidonic acid could not be expected from the conventional idea.
- the present inventors have paid attention to the fact that the vasorelaxant response of rats decreases with aging, and completed the present invention by finding out the effects of arachidonic acid, which overturns conventional thinking.
- the active ingredient of the present invention is arachidonic acid, and any compound containing arachidonic acid as a constituent fatty acid can be used.
- Compounds containing arachidonic acid as a constituent fatty acid include arachidonic acid salts, Examples thereof include potassium salt, sodium salt and the like.
- lower alcohol 'esters of arachidonic acid such as methyl arachidonic acid ester and arachidonic acid ethynole ester, etc.
- arachidonic acid salts examples thereof include potassium salt, sodium salt and the like.
- lower alcohol 'esters of arachidonic acid such as methyl arachidonic acid ester and arachidonic acid ethynole ester, etc.
- a triglyceride containing a triglyceride in which part or all of the constituent fatty acids which are the active ingredients of the present invention is arachidonic acid (a triglyceride containing arachidonic acid) is used.
- Cel can be used.
- triglycerides containing arachidonic acid the proportion of arachidonic acid in the total fatty acids constituting the triglycerides is at least 20% by weight (W / W), preferably 30%. Fats and oils (triglycerides) of more than 40% by weight, more preferably more than 40% by weight, are the preferred forms for food applications.
- any one obtained by culturing a microorganism having the ability to produce arachidonic acid-containing fats and oils (triglycerides) can be used.
- microorganisms capable of producing arachidonic acid-containing fats and oils (triglycerides) include genus Mortierella, genus Conidiobolus, genus Pythium, and phytium.
- the microorganisms belonging to the subgenus Mortierella belonging to the genus Mortierella (Mortierella) include, for example, Mortierella 'Erlongata (Mortierel la elongata), Monoretie herella.
- Moraella grophila Mortierella alpina and the like.
- strains were obtained from the Osaka Yeast Research Institute (IF0) and the United States American Type 'Type' Ricilia I. Culture Collection (ATCC). It can be obtained without any restrictions from the Central Rural Bureau voor Schimmelcultures (CBS). It is also possible to use a strain of strain Mortierella erogata SAM0219 (Microorganism No. 8703) (Microorganism No. 1239) isolated from soil by the research group of the present invention.
- CBS Central Rural Bureau voor Schimmelcultures
- a spore, hypha or a preculture liquid obtained by pre-culturing the strain is inoculated into a liquid medium or a solid medium and cultured.
- the carbon sources include glucose, fructose, xylose, saccharose, manolose, soluble native starch, molasses, glycerol, mannitol, etc. Any commonly used one can be used, but is not limited to these.
- Nitrogen sources include natural sources such as peptone, yeast extract, malt extract, meat extract, casamino acid, corn steep liquor, soy protein, defatted soybean, cottonseed cas, etc., as well as urea. And the like, as well as inorganic nitrogen sources such as sodium nitrate, ammonium nitrate, and ammonium sulfate.
- inorganic nitrogen sources such as sodium nitrate, ammonium nitrate, and ammonium sulfate.
- phosphate, magnesium sulfate Inorganic salts such as nesium, iron sulfate, copper sulfate and vitamins can also be used as trace nutrients. These medium components are not particularly limited as long as they do not impair the growth of microorganisms.
- the carbon source is 0 ::! A concentration of ⁇ 40% by weight, preferably 1 ⁇ 25% by weight is good.
- the initial addition of nitrogen source is 0.1 to 10% by weight, preferably 0 :! A nitrogen source
- an oil or fat (triglyceride) containing arachidonic acid of 45% by weight (W / W)% or more can be used as the active ingredient of the present invention.
- the initial carbon source concentration is 1 to 8% by weight, preferably 1 to 4% by weight, and the carbon source is added sequentially only during the bacterial growth phase and the initial period of the fat and oil accumulation phase.
- the total is 2-20% by weight, preferably 5-15% by weight.
- the sequential addition of the carbon source during the cell growth phase and the initial period of the oil and fat accumulation phase depends on the initial nitrogen source concentration, and should be added after the 7th day of culture, preferably after the 6th day of culture.
- the carbon source concentration in the medium after day 4 of culture is reduced to 0 to obtain an oil or fat (triglyceride) containing at least 45% by weight of arachidonic acid.
- the cultivation temperature of the arachidonic acid-producing bacterium depends on the microorganism used, but it is 5 to 40 ° C, preferably 20 to 30 ° C, and the cells are cultured at 20 to 30 ° C. After the cultivation, the culture can be continued at 5 to 20 ° C.
- the cultivation is usually performed for 2 to 30 days, preferably for 5 to 20 days, more preferably for 5 to 15 days.
- arachidonic acid-containing fats and oils in addition to controlling the concentration of the carbon source in the medium, arachidonic acid-containing fats and oils can be selectively hydrolyzed to obtain arachidonic acid-rich fats and oils.
- the lipase used for this selective hydrolysis does not have the regiospecificity of triglycerides, and the hydrolysis activity decreases in proportion to the number of double bonds, so that fatty acids other than polyunsaturated fatty acids are used. Is hydrolyzed.
- fats and oils (triglycerides) containing high content of arachidonic acid obtained by selectively hydrolyzing arachidonic acid-containing fats and oils can be used as the active ingredient of the present invention.
- the ratio of arachidonic acid to the total fatty acids in the arachidonic acid-containing fats and oils (triglycerides) of the present invention is desirably higher for the purpose of eliminating the effects of other fatty acids, but is limited to a higher ratio.
- the absolute amount of arachidonic acid may be a problem, and fats and oils containing 10% by weight or more of arachidonic acid (triglyceride) Can be used in practice.
- a medium-chain fatty acid is bonded to the 1,3-position and arachidonic acid is bonded to the 2-position.
- a medium chain fatty acid at the 1,3-position and a triglyceride having arachidonic acid at the 2-position are 5 mol% or more, preferably 10 mol% or more, and more preferably 20 mol%.
- fats and oils (triglycerides) containing at least 30 mol% can be used.
- Medium-chain fatty acids selected from fatty acids having 6 to 12 carbon atoms can be used.
- the fatty acid having 6 to 12 carbon atoms includes, for example, caprylic acid or capric acid, and in particular, 1,3-caproloylo-2-arachidonyl-glycerol '(hereinafter referred to as “glycerol”). 8A8 ").
- glycerol 1,3-caproloylo-2-arachidonyl-glycerol '(hereinafter referred to as “glycerol”). 8A8 ").
- These triglycerides, in which the medium-chain fatty acid is bonded to the 1,3-position and arachidonic acid is bonded to the 2-position are the most suitable fats and oils (triglycerides) for the elderly. It becomes.
- the fatty acid characteristics of this lipase are high for saturated fatty acids, and arachidonic acid has a hard-to-cut characteristic.
- Triglycerides with arachidonic acid at the-position are the most suitable fats and oils (triglycerides).
- One of the specific methods for producing triglycerides in which a medium-chain fatty acid is bonded to the 1,3-position and arachidonic acid is bonded to the 2-position is an oil containing arachidonic acid (triglyceride). Lipase that acts only on the 1,3-position ester bond of triglyceride in the presence of It can be manufactured with
- the raw material fat is triglyceride containing arachidonic acid as a constituent fatty acid.
- the ratio of arachidonic acid is high relative to the total fatty acids constituting the triglyceride, Prevents the decrease in reaction yield due to the increase in unreacted fats and oils (triglycerides as raw materials and triglycerides in which only one of the 1,3-position fatty acids is a medium-chain fatty acid). Therefore, the temperature is set to 30 to 50 ° C, preferably 40 to 50 ° C, higher than the normal enzyme reaction temperature of 20 to 30 ° C.
- Lipases that specifically act on the 1,3-position ester bond of triglyceride include, for example, genus Rhizopus, genus Rhizomucor, and genus Aspergillus. ) which microbial force s production, such as the genus, and porcine spleen lipase can and Ageruko. As such a lipase, a commercially available lipase can be used.
- lipase of Rhizopus delemar (Talipase, manufactured by Tanabe Seiyaku Co., Ltd.), lipase of Rhizomucor miehei (manufactured by Novo Nordisk, Inc.) Bozym IM), Apergillus niger lipase (Amano Pharmaceutical Co., Ltd., Lipase A), and the like, but are not limited to these enzymes. Any 3-position-specific lipase can be used.
- the above lipase was used in an immobilized carrier for the purpose of increasing the heat resistance of the enzyme in order to increase the reaction temperature to 30 ° C or higher, preferably 40 ° C or higher for the purpose of increasing the reaction efficiency. It is desirable to use lipase.
- the immobilization carrier is a porous chamber (high-porous) resin, and is a ion-exchange resin carrier having a pore diameter of about 100 ⁇ or more, for example, a force S such as Dowex MARATHON WBA.
- the present invention is not limited to these immobilized carriers, and is an immobilized carrier to which heat resistance can be added. All can be used.
- An aqueous solution of the 1,3-position specific lipase is suspended in 0.5 to 20 times the weight of the immobilized carrier 1, and 2 to 5 times the amount of cold acetate to the suspension (for example, -80 ° C) with stirring to form a precipitate.
- the precipitate can be dried under reduced pressure to prepare the immobilized enzyme.
- a simpler method is to dissolve 0.05 to 0.4 times the 1,3-position specific lipase in a minimum amount of water with respect to the immobilized carrier 1, and stir the immobilized carrier. Can be mixed and dried under reduced pressure to prepare an immobilized enzyme.
- the lipase is immobilized on the carrier, but it does not show any transesterification activity as it is, and is preferably used in a substrate to which 10% by weight (w / v) of water has been added.
- the immobilized enzyme can be most efficiently activated and provided for production.
- the amount of water added to the reaction system is extremely important. If water is not contained, transesterification becomes difficult to proceed, and if the amount of water is large, hydrolysis occurs. The recovery of glyceride is reduced (diglyceride and monoglyceride are produced when hydrolysis occurs).
- the immobilized enzyme activated by the pretreatment the amount of water added to the reaction system is not important, and the transesterification reaction can be performed efficiently even in a system that does not contain water at all. Can get up.
- pretreatment can be omitted by selecting the type of enzyme preparation.
- a method for producing a food or drink having an effect of preventing or ameliorating a symptom or disease caused by aging of blood vessels wherein arachidonic acid and / or a compound having arachidonic acid as a constituent fatty acid is used alone or arachidonic acid is used. It is practically not contained, or even if it is contained, it can be blended with a small amount of food and drink ingredients.
- the small amount refers to arachidonic acid as a raw material of food or drink, or a food composition containing the arachidonic acid, which is ingested by a person per day of the present invention described below. Means that the intake of arachidonic acid has not been reached.
- foods that contain fats and oils include natural foods that contain fats and oils, such as meat, fish, or nuts, foods that add fats and oils when cooking soups, foods that use fats and oils as a heating medium such as donuts, butter, etc.
- Fats and oils, processed foods to which oils and fats are added at the time of processing such as cookies, and foods to which fats and oils are sprayed or applied at the time of finishing such as hard biscuits.
- it can be added to agricultural foods, fermented foods, livestock foods, seafood foods, or beverages that do not contain fats and oils.
- they may be in the form of functional foods or pharmaceuticals, for example, enteral nutrition, powders, granules, troches, oral liquids, suspensions, emulsions, syrups, etc. It may be.
- composition of the present invention generally comprises a food or beverage in addition to the active ingredient of the present invention. It may contain various carriers and additives used for pharmaceuticals or quasi-drugs. It is particularly desirable to include an antioxidant for the purpose of preventing the active ingredient of the present invention from being oxidized.
- Antioxidants include, for example, tocoprolols, flavone derivatives, phyllodulcines, kojic acid, gallic acid derivatives, catechins, fuchic acid, gossypol, pyrazine derivatives, sesamol, guaiaol, guaiac acid, P-coumarin Natural antioxidants such as acid, nordihydroguatetic acid, sterols, terpenes, nucleic acid bases, carotinoides, redanane, etc. and ascorbic acid palmitic acid ester, ascorbic acid stearate Phosphoric acid esters.
- tocoprolols flavone derivatives, phyllodulcines, kojic acid, gallic acid derivatives, catechins, fuchic acid, gossypol, pyrazine derivatives, sesamol, guaiaol, guaiac acid, P-coumarin Natural antioxidants such as acid, nordihydro
- Butynolexyhydroxyannole BHA
- Butylhydroxytonolene BHT
- 4-Hydroxymethyl'-2,6-di- Synthetic antioxidants such as t-butylphenol (HMBP) can be mentioned.
- tocopherones For tocopherones, a-tocopherone,] 3—tocopherone, ⁇ -tocopherone, ⁇ _tocopherone, ⁇ tocopherone, ⁇ - Tocopherolone, ⁇ tocophere and tocophere-norester (such as tocopherol diacid), and tocotrienol as related compounds Can be.
- carotenoids include, for example,
- composition of the present invention may contain, as carriers, various carrier carriers, extenders, diluents, extenders, dispersants, excipients, binder solvents (eg, Water, ethanol, vegetable oils), solubilizers, buffers, solubilizers, gelling agents, suspending agents, flour, rice flour, starch, corn starch, polysaccharides, minolek protein, collagen, rice Oil, lecithin and the like.
- additives include vitamins, sweeteners, organic acids, coloring agents, fragrances, anti-wetting agents, and famers. , Electrolytes, minerals, nutrients, antioxidants, preservatives, fragrances, humectants, natural food extracts, vegetable extracts, etc., but are not limited to these.
- arachidonic acid The main active ingredient of arachidonic acid and compounds having arachidonic acid as a constituent fatty acid is arachidonic acid.
- the daily intake of arachidonic acid from meals is reported to be 0.14 g in the Kanto area and 0.19-0.20 g in the Kansai area (Lipid nutrition 4, 73-82, 1995).
- the daily intake of an adult for example, assuming a body weight of 60 kg
- the compound containing arachidonic acid as a constituent fatty acid of the present invention is calculated as the amount of arachidonic acid.
- O.OOlg-20 g preferably 0.01 g-10 g, more preferably 0.05-5 g, and most preferably 0.1 lg_2 g.
- the absolute amount of arachidonic acid to be incorporated into the food is also important.
- the absolute amount to be added to food and drink varies depending on the intake of the food and drink to be added, triglyceride containing triglyceride in which some or all of the constituent fatty acids are arachidonic acid is used.
- the content of arachidonic acid is 0.001% by weight or more, preferably 0.01% by weight / degree. As described above, the content is more preferably 0.1% by weight or more.
- a triglyceride in which a medium-chain fatty acid is bonded to the 1,3-position and arachidonic acid is bonded to the 2-position is added to a food or drink, 0.000003% by weight or more is added. Preferably it is at least 0.003% by weight, more preferably at least 0.03% by weight.
- composition of the present invention when used as a medicament, it can be produced according to a method commonly used in the technical field of formulation, for example, a method described in the Japanese Pharmacopoeia or a method analogous thereto.
- the active ingredient in the composition is not particularly limited as long as the object of the present invention is achieved, and can be used in an appropriate mixing ratio.
- the composition of the present invention When the composition of the present invention is used as a pharmaceutical, it is preferable to administer the composition in a dosage unit form, and particularly preferable is oral administration.
- the dose of the composition of the present invention varies depending on age, body weight, symptoms, frequency of administration and the like. For example, for adults (about 60 kg), the arachidonic acid and / or arachidonic acid of the present invention per day can be used. Is usually about 0.001 g to 20 g, preferably 0.1 Olg to: L0 g, more preferably 0.05 to 5 g, most preferably 0.05 to 5 g in terms of arachidonic acid. It is advisable to administer 0 to 2 g of lg once to 3 times a day.
- Polyunsaturated fatty acids mainly arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid, are bound to the phospholipids constituting the cell membrane of blood vessels as constituent fatty acids.
- a combination with eicosapentaenoic acid and / or docosahexaenoic acid is desirable.
- a food or drink having a arachidonic acid Z eicosapentaenoic acid and / or docosahexaenoic acid ratio in the range of 0.25 to 8 is most desirable.
- Mortierella alpina CBS754.68 was used as the arachidonic acid producing bacterium. Glucose 1.8%, defatted soybean meal 3.1%, soybean oil 0. 1%, KH 2 P0 4 0. 3%, Na 2 S0 4 0. 1%, CaCl 2 - 2H 2 0 0. 05% ⁇ fine MgCl 2 - medium 6kL containing 6H 2 0 0. 05%, prepared 10kL culture tank, initial The pH was adjusted to 6.0. 30 L of the preculture was inoculated, and aeration-stirred culture was performed for 8 days at a temperature of 26 ° C, aeration of 360 ra 3 / h, and a tank pressure of 200 kPa.
- the number of agitation was adjusted so that the dissolved oxygen concentration was maintained at 10 to 15 ppm.
- the glucose concentration in the medium was maintained at 0.5-1% by the fed-batch method until day 4 so that the glucose concentration in the medium was within the range of 1-2.5%. (The above% means weight (W / V)%).
- the cells containing triglyceride containing arachidonic acid as a constituent fatty acid are collected by filtration and drying, and oils and fats are extracted from the obtained cells by hexane extraction.
- arachidonic acid-containing triglycerides triglycerides in which part or all of the constituent fatty acids are arachidonic acid
- Triglyceride contained 150 kg was obtained.
- the resulting fats and oils (triglycerides) were methylesterified and the resulting fatty acid methylesters were analyzed by gas chromatography.
- the ratio of arachidonic acid to total fatty acids was 40. 84%.
- Palmitic acid, stearic acid, oleic acid, linoleic acid, '-linolenic acid, dihomo- ⁇ -linolenic acid, etc. were 11.63%, 7.45%, 7.73%, respectively. , 9.14%, 2.23% and 3.27%.
- the arachidonic acid-containing oil (triglyceride) (SUNTGA40S) is converted into ethyl ester, and a fatty acid ethyl ester mixture containing 40% arachidonic acid ethyl ester is subjected to conventional high-performance liquid chromatography. And 99% of arachidonic acid ethyl ester were separated and purified.
- ion-exchange resin carrier Dow Chemical
- ion-exchange resin carrier Dow Chemical
- 80 ml of an aqueous solution of Rhizopus de lemar lipase Rhizopus de lemar lipase present end, 12.5%: Tanabe Seiyaku Co., Ltd.
- 240 ml of Disturb cold acetate _80 ° C
- Vitamin E 0.05 0.05
- the food consumption of SUNTGA40S05 rat is about 20 g, and the daily intake of SUNTGA40S per rat is 100 mg. Since 40% of the total fatty acids bound to the arachidonic acid-containing fat (SUNTGA40S) prepared in Reference Example 1 are arachidonic acid, the daily intake of arachidonic acid per rat is 40 mg. And This 40 rag is equivalent to 133 mg / 60 kg / day when converted to human intake. At 3 months of breeding (22 months old for old rats and 4 months old for young rats), the thoracic aorta was excised, and a part was subjected to an in vitro vascular relaxation test. The remaining vessels were used for fatty acid composition analysis.
- Vitamin E 0.05 0.05
- the experimental diet was designed so that the daily intake of arachidonic acid per rat of the 8A8 formula feed group was 40 mg . This 40 mg is equivalent to 133 rag / 60 kg / day when converted to human intake.
- Example 3 Preparation of a fat / oil (triglyceride) blending compound containing arachidonic acid as a constituent fatty acid
- the proportions of the arachidonic acid-containing oil (triglyceride) 50% by weight and the fish oil (tuna oil: eicosapentaenoic acid and docosahexaenoic acid in the total fatty acids) obtained in Reference Example 1 were 5. (1% and 26.5%) were mixed at 50% by weight, and 0.05% by weight of vitamin E oil was mixed to prepare a content 3. 80% by weight of arachidonic acid-containing oil (triglyceride) and fish oil
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04793331A EP1679068A4 (en) | 2003-10-29 | 2004-10-28 | COMPOSITION TO PREVENT OR PREVENT SYMPTOMS OR DISEASES RELATED TO THE AGING OF BLOOD VESSELS |
CA2512133A CA2512133C (en) | 2003-10-29 | 2004-10-28 | Compositions of arachidonic acid for preventing or alleviating symptoms or diseases due to aging of blood vessels |
US10/541,073 US20060088573A1 (en) | 2003-10-29 | 2004-10-28 | Composition having action preventing or alleviating symtoms or diseases due to aging of blood vessels |
AU2004283610A AU2004283610B2 (en) | 2003-10-29 | 2004-10-28 | Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging |
KR1020057012329A KR101245364B1 (ko) | 2003-10-29 | 2004-10-28 | 혈관의 노화에 기인하는 증상 또는 질환을 예방 또는 완화하는 작용이 있는 조성물 |
CN200480001751XA CN1723016B (zh) | 2003-10-29 | 2004-10-28 | 对由血管老化引起的症状或疾病具有预防或减缓作用的组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-369147 | 2003-10-29 | ||
JP2003369147A JP4522075B2 (ja) | 2003-10-29 | 2003-10-29 | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005039559A1 true WO2005039559A1 (ja) | 2005-05-06 |
Family
ID=34510371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/016351 WO2005039559A1 (ja) | 2003-10-29 | 2004-10-28 | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060088573A1 (ja) |
EP (1) | EP1679068A4 (ja) |
JP (1) | JP4522075B2 (ja) |
KR (1) | KR101245364B1 (ja) |
CN (1) | CN1723016B (ja) |
AU (1) | AU2004283610B2 (ja) |
CA (1) | CA2512133C (ja) |
TW (3) | TWI445528B (ja) |
WO (1) | WO2005039559A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
PT1542670E (pt) * | 2002-09-24 | 2013-07-11 | Suntory Holdings Ltd | Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável |
JP2006083136A (ja) * | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
JP5697293B2 (ja) * | 2005-06-30 | 2015-04-08 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
DE102005058369A1 (de) * | 2005-12-06 | 2007-06-14 | Lts Lohmann Therapie-Systeme Ag | Ungesättigte Fettsäuren als Thrombin-Inhibitoren |
US20090246185A1 (en) | 2006-03-13 | 2009-10-01 | Kaneka Corporation | Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent |
KR101578498B1 (ko) * | 2006-12-28 | 2015-12-18 | 산토리 홀딩스 가부시키가이샤 | 신경 재생제 |
JP2009019025A (ja) * | 2007-07-13 | 2009-01-29 | Suntory Ltd | 非ヒト動物の老化又は痴呆に伴う疾患又は症状の改善剤 |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
EP2211881A4 (en) * | 2007-11-01 | 2012-01-04 | Wake Forest University School Of Medicine | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AFFECTING MAMMALS |
WO2024047483A1 (en) * | 2022-08-29 | 2024-03-07 | Fundação Calouste Gulbenkian | Arachidonic acid for preventing or decreasing post-operative bleeding |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001031586A (ja) * | 1999-07-14 | 2001-02-06 | Sunstar Inc | 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物 |
WO2002102394A2 (en) * | 2001-06-18 | 2002-12-27 | Neptune Technologies & Bioressources Inc. | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
JP2003504333A (ja) * | 1999-07-14 | 2003-02-04 | ラクスディル リミテッド | 必須脂肪酸およびホモシステイン低下剤を含有する製剤および栄養組成物 |
JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2003113120A (ja) * | 2001-08-03 | 2003-04-18 | Takeda Chem Ind Ltd | 徐放性医薬 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4668704A (en) * | 1982-08-09 | 1987-05-26 | Regents Of The University Of California | Method for protecting and healing gastro-duodenal mucosa and the liver of mammals |
US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
AU683027B2 (en) * | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
GB9423625D0 (en) * | 1994-11-23 | 1995-01-11 | Scotia Holdings Plc | Fortified fruit juice |
US5583019A (en) * | 1995-01-24 | 1996-12-10 | Omegatech Inc. | Method for production of arachidonic acid |
US6080787A (en) * | 1997-02-21 | 2000-06-27 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
FR2762993B1 (fr) * | 1997-05-06 | 1999-08-13 | Inst Rech Biolog Sa | Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique |
US5902807A (en) * | 1997-05-12 | 1999-05-11 | Antti Haapalinna | Method for the treatment of mental illness in mammals and a composition therefor |
ES2188855T3 (es) * | 1997-07-22 | 2003-07-01 | Nestle Sa | Composicion lipida para formula infantil y procedimiento de preparacion. |
US6225444B1 (en) * | 1998-02-10 | 2001-05-01 | Protarga, Inc. | Neuroprotective peptides and uses thereof |
US20020019444A1 (en) * | 2000-05-08 | 2002-02-14 | Edward Hogestatt | Anandamide and structurally related lipids as vanilloid receptor modulators |
US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
WO2001091745A2 (en) * | 2000-05-30 | 2001-12-06 | The Brigham And Women's Hospital, Inc. | Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions |
GB0016045D0 (en) * | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
EP1413315A4 (en) * | 2001-08-03 | 2006-08-16 | Takeda Pharmaceutical | DRUGS WITH CONTINUOUS RELEASE |
US6689810B2 (en) * | 2001-08-21 | 2004-02-10 | Cellular Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
US7998712B2 (en) * | 2002-09-13 | 2011-08-16 | Suntory Holdings Limited | Process for production of transesterified oils/fats or triglycerides |
PT1542670E (pt) * | 2002-09-24 | 2013-07-11 | Suntory Holdings Ltd | Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável |
US20060217368A1 (en) * | 2003-04-18 | 2006-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Drug for nerve regeneration |
-
2003
- 2003-10-29 JP JP2003369147A patent/JP4522075B2/ja not_active Expired - Fee Related
-
2004
- 2004-10-28 CA CA2512133A patent/CA2512133C/en not_active Expired - Fee Related
- 2004-10-28 CN CN200480001751XA patent/CN1723016B/zh active Active
- 2004-10-28 AU AU2004283610A patent/AU2004283610B2/en not_active Ceased
- 2004-10-28 KR KR1020057012329A patent/KR101245364B1/ko active IP Right Grant
- 2004-10-28 WO PCT/JP2004/016351 patent/WO2005039559A1/ja active Application Filing
- 2004-10-28 EP EP04793331A patent/EP1679068A4/en not_active Withdrawn
- 2004-10-28 US US10/541,073 patent/US20060088573A1/en not_active Abandoned
- 2004-10-29 TW TW093132969A patent/TWI445528B/zh not_active IP Right Cessation
- 2004-10-29 TW TW102125771A patent/TWI503117B/zh active
- 2004-10-29 TW TW104113281A patent/TW201529067A/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001031586A (ja) * | 1999-07-14 | 2001-02-06 | Sunstar Inc | 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物 |
JP2003504333A (ja) * | 1999-07-14 | 2003-02-04 | ラクスディル リミテッド | 必須脂肪酸およびホモシステイン低下剤を含有する製剤および栄養組成物 |
WO2002102394A2 (en) * | 2001-06-18 | 2002-12-27 | Neptune Technologies & Bioressources Inc. | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2003113120A (ja) * | 2001-08-03 | 2003-04-18 | Takeda Chem Ind Ltd | 徐放性医薬 |
Non-Patent Citations (3)
Title |
---|
HORROBIN, D.F.: "Abnormal Membrane Concentration of 20 and 22-Carbon Essential Fatty Acids: A Common Link Between Factors and Coronary and Peripheral Vascular Disease", PROSTAGLANDINS LEUKOTRIENS AND ESSENTIAL FATTY ACIDS, vol. 53, 1995, pages 385 - 396, XP002983674 * |
MACKAY, K.: "Arachidonic acid protects neonatal rat cardiac myocytes from ischaemic injury through protein kinase C", CARDIOVASCULAR RESEARCH, vol. 50, 2001, pages 65 - 74, XP001134927 * |
See also references of EP1679068A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP4522075B2 (ja) | 2010-08-11 |
TW200522939A (en) | 2005-07-16 |
TWI445528B (zh) | 2014-07-21 |
US20060088573A1 (en) | 2006-04-27 |
AU2004283610A1 (en) | 2005-05-06 |
AU2004283610B2 (en) | 2011-02-03 |
CA2512133A1 (en) | 2005-05-06 |
CA2512133C (en) | 2013-10-01 |
EP1679068A1 (en) | 2006-07-12 |
TW201350112A (zh) | 2013-12-16 |
TWI503117B (zh) | 2015-10-11 |
TW201529067A (zh) | 2015-08-01 |
KR20060113360A (ko) | 2006-11-02 |
CN1723016A (zh) | 2006-01-18 |
CN1723016B (zh) | 2012-04-04 |
EP1679068A4 (en) | 2010-09-29 |
JP2005132758A (ja) | 2005-05-26 |
KR101245364B1 (ko) | 2013-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101989390B1 (ko) | 뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선작용을 가지는 조성물 | |
AU2005283697B2 (en) | Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders | |
AU2005283696B2 (en) | Composition with preventive or improvement effect on stress-induced brain function impairment and related symptoms or diseases | |
JP5967855B2 (ja) | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 | |
JP4633048B2 (ja) | 日内リズム正常化組成物 | |
WO2005039559A1 (ja) | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 | |
JP5496163B2 (ja) | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 | |
JP2009219500A (ja) | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004283610 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006088573 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2512133 Country of ref document: CA Ref document number: 2004801751X Country of ref document: CN Ref document number: 1020057012329 Country of ref document: KR Ref document number: 10541073 Country of ref document: US Ref document number: 2910/DELNP/2005 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2004283610 Country of ref document: AU Date of ref document: 20041028 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004793331 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004283610 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 10541073 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004793331 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057012329 Country of ref document: KR |